共 88 条
[1]
Constantinescu SE(2016)Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis Expert Rev Clin Pharmacol 9 49-57
[2]
Constantinescu CS(2013)The cost burden of multiple sclerosis in the United States: a systematic review of the literature J Med Econ 16 639-647
[3]
Adelman G(2018)Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis Curr Med Res Opin 34 1361-1371
[4]
Rane SG(2016)Laquinimod in the treatment of multiple sclerosis: a review of the data so far Drug Des Devel Ther 10 1111-1118
[5]
Villa KF(2017)Laquinimod safety profile: pooled analyses from the ALLEGRO and BRAVO trials Int J MS Care 19 16-24
[6]
Siddiqui MK(2012)Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis J Neuroimmunol 251 45-54
[7]
Khurana IS(2004)Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats J Neuroimmunol 156 3-9
[8]
Budhia S(2010)Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis J Neuroimmunol 227 133-143
[9]
Thone J(2002)Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue Neuropharmacology 42 731-739
[10]
Linker RA(2011)Oral treatment for multiple sclerosis Lancet Neurol 10 1026-1034